ID17088A - Tablet galantamin hidrobromida yang sangat mudah larut - Google Patents

Tablet galantamin hidrobromida yang sangat mudah larut

Info

Publication number
ID17088A
ID17088A IDP972025A ID972025A ID17088A ID 17088 A ID17088 A ID 17088A ID P972025 A IDP972025 A ID P972025A ID 972025 A ID972025 A ID 972025A ID 17088 A ID17088 A ID 17088A
Authority
ID
Indonesia
Prior art keywords
galantamin
hydrobromides
tablet
easy solutions
solutions
Prior art date
Application number
IDP972025A
Other languages
English (en)
Indonesian (id)
Inventor
Paul Marie Victor Gilis
Valentin Florent Victor Conde
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of ID17088A publication Critical patent/ID17088A/id

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IDP972025A 1996-06-14 1997-06-13 Tablet galantamin hidrobromida yang sangat mudah larut ID17088A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP96201676 1996-06-14

Publications (1)

Publication Number Publication Date
ID17088A true ID17088A (id) 1997-12-04

Family

ID=8224084

Family Applications (1)

Application Number Title Priority Date Filing Date
IDP972025A ID17088A (id) 1996-06-14 1997-06-13 Tablet galantamin hidrobromida yang sangat mudah larut

Country Status (33)

Country Link
US (2) US6099863A (ja)
EP (1) EP0915701B1 (ja)
JP (1) JP4172820B2 (ja)
KR (1) KR100358676B1 (ja)
CN (1) CN1102390C (ja)
AR (2) AR008237A1 (ja)
AT (1) ATE285777T1 (ja)
AU (1) AU726212B2 (ja)
BG (1) BG64168B1 (ja)
BR (1) BR9709729A (ja)
CA (1) CA2257431C (ja)
CZ (1) CZ295226B6 (ja)
DE (1) DE69732113T2 (ja)
DK (1) DK0915701T3 (ja)
EA (1) EA001193B1 (ja)
EE (1) EE03337B1 (ja)
ES (1) ES2235234T3 (ja)
HK (1) HK1019703A1 (ja)
HR (1) HRP970321B1 (ja)
ID (1) ID17088A (ja)
IL (1) IL127519A (ja)
MY (1) MY121669A (ja)
NO (1) NO322892B1 (ja)
NZ (1) NZ333280A (ja)
PL (1) PL189329B1 (ja)
PT (1) PT915701E (ja)
SI (1) SI0915701T1 (ja)
SK (1) SK284620B6 (ja)
TR (1) TR199802592T2 (ja)
TW (1) TW506836B (ja)
UA (1) UA62930C2 (ja)
WO (1) WO1997047304A1 (ja)
ZA (1) ZA975281B (ja)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440457B1 (en) * 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
TW506836B (en) * 1996-06-14 2002-10-21 Janssen Pharmaceutica Nv Fast-dissolving galanthamine hydrobromide tablet
CA2358062C (en) 1998-12-24 2006-12-19 Janssen Pharmaceutica N.V. Controlled release galantamine composition
US20050063998A1 (en) * 1999-10-26 2005-03-24 Francois Marc Karel Jozef Oral solution containing galantamine and a sweetening agent
US6627223B2 (en) 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
JP2003530437A (ja) * 2000-04-13 2003-10-14 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ Ａβ４２低下物質
SE521512C2 (sv) * 2001-06-25 2003-11-11 Niconovum Ab Anordning för administrering av en substans till främre delen av en individs munhåla
US9358214B2 (en) 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
US6500454B1 (en) * 2001-10-04 2002-12-31 Eurand Pharmaceuticals Ltd. Timed, sustained release systems for propranolol
DE10235556A1 (de) * 2002-08-03 2004-02-19 Hf Arzneimittelforschung Gmbh Medikament und Verfahren zur Verringerung des Alkohol- und/oder Tabakkonsums
US20040097484A1 (en) * 2002-11-14 2004-05-20 Marc Cantillion Once a day galantamine pharmaceutical compositions and methods of use
FI3473251T3 (fi) 2002-12-20 2024-01-09 Niconovum Ab Nikotiini-selluloosa-kombinaatio
US8367111B2 (en) 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
WO2004071431A2 (en) * 2003-02-05 2004-08-26 Myriad Genetics, Inc. Method and composition for treating neurodegenerative disorders
US7521481B2 (en) * 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
DE10338544B4 (de) * 2003-08-19 2017-08-31 Janssen Pharmaceutica N.V. Buccale Formulierungen des Galanthamins und deren Anwendungen
SI2133084T1 (sl) * 2003-08-26 2015-07-31 Shire Biopharmaceuticals Holdings Ireland Limited Farmacevtska formulacija obsegajoča lantanove spojine
US20050143350A1 (en) * 2003-11-19 2005-06-30 Seed John C. Combination drug therapy to treat obesity
WO2005051489A2 (en) * 2003-11-28 2005-06-09 Ranbaxy Laboratories Limited Fast dissolving solid oral dosage forms of galanthamine
WO2005065662A1 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Solid dosage formulations of galantamine
WO2005065661A2 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Immediate, controlled and sustained release formulations of galanthamine
EP2340813A1 (en) * 2003-12-31 2011-07-06 Actavis Group PTC ehf. Solid dosage formulations of galantamine
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020853A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
US8747895B2 (en) 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
PL2813225T3 (pl) * 2004-09-24 2018-11-30 University Of Maryland, Baltimore Sposób leczenia zatrucia związkami fosforoorganicznymi
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
EP2417969A1 (en) 2004-10-21 2012-02-15 Aptalis Pharmatech, Inc. Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
EP1819681B1 (en) * 2004-11-23 2009-08-12 Warner-Lambert Company LLC 7-(2h-pyrazol-3-yl)-3,5-dihydroxy-heptanoic acid derivatives as hmg co-a reductase inhibitors for the treatment of lipidemia
US20080145422A1 (en) * 2005-02-10 2008-06-19 Roxane Laboratories, Inc. Galantamine tablet formulation
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
GB0516604D0 (en) * 2005-08-12 2005-09-21 Sandoz Ag Rapidly dispersing/disintegrating compositions
US8168219B2 (en) * 2005-11-30 2012-05-01 Isp Investments Inc. Synergistic binder composition, method for making same, and tablets of an active and said binder having advantageous hardness and friability
AU2007224584A1 (en) 2006-03-16 2007-09-20 Niconovum Ab Improved snuff composition
CA2648495C (en) * 2006-04-26 2016-07-05 Alphapharm Pty Ltd Controlled release formulations comprising uncoated discrete unit(s) and an extended release matrix
GB0612540D0 (en) * 2006-06-23 2006-08-02 Novartis Ag Galenical formulations of organic compounds
EP2043613A1 (en) * 2006-07-14 2009-04-08 Fmc Corporation Solid form
CN100438917C (zh) * 2006-07-20 2008-12-03 山东聊城阿华制药有限公司 一种微晶纤维素乳糖的制备方法
WO2008062426A2 (en) * 2006-08-02 2008-05-29 Emcure Pharmaceuticals Limited Formulation of benzazepine derivatives
WO2008051599A2 (en) 2006-10-27 2008-05-02 Medivation Neurology, Inc. Combination therapies for treating alzheimer's disease using i. a. dimebon and dolepezil
US20080311162A1 (en) * 2007-05-16 2008-12-18 Olivia Darmuzey Solid form
UY31531A1 (es) * 2007-12-17 2009-08-03 Sales derivadas de 8-oxoadenina composiciones farmacéuticas que las contienen y su uso en terapia como moduladores de receptor tipo toll (tlr)
EP2116232B1 (de) 2008-05-09 2012-02-15 Ratiopharm GmbH Galanthaminhaltiges Arzneimittel mit kontrollierter Freisetzung
CN102958515A (zh) 2009-12-02 2013-03-06 阿普塔利斯制药有限公司 非索非那定微胶囊及含有非索非那定微胶囊的组合物
WO2011151359A1 (en) 2010-06-02 2011-12-08 Noscira, S.A. Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative
JP5656258B2 (ja) * 2011-03-09 2015-01-21 塩野義製薬株式会社 ガランタミンを含有する口腔内崩壊錠剤
EP3033082B1 (en) 2013-08-16 2021-06-16 Universiteit Maastricht Treatment of cognitive impairment with pde4 inhibitor
CN106822008A (zh) * 2017-01-11 2017-06-13 江苏艾兰得营养品有限公司 一种维生素d速溶制剂及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3506276C1 (de) * 1985-02-22 1986-04-24 Meggle Milchindustrie Gmbh & Co Kg, 8094 Reitmehring Direkttablettiermittel
US4663318A (en) * 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
US6150354A (en) * 1987-01-15 2000-11-21 Bonnie Davis Compounds for the treatment of Alzheimer's disease
EP0515301A3 (en) * 1991-05-14 1993-06-16 Ernir Snorrason Improvements in benzodiazepine treatment by cholinesterterase inhibitors
US5336675A (en) * 1991-05-14 1994-08-09 Ernir Snorrason Method of treating mania in humans
TW506836B (en) * 1996-06-14 2002-10-21 Janssen Pharmaceutica Nv Fast-dissolving galanthamine hydrobromide tablet

Also Published As

Publication number Publication date
AR008237A1 (es) 1999-12-29
EA001193B1 (ru) 2000-12-25
BR9709729A (pt) 1999-08-10
DK0915701T3 (da) 2005-04-25
HK1019703A1 (en) 2000-02-25
EA199900026A1 (ru) 1999-06-24
NO985815L (no) 1998-12-11
NO985815D0 (no) 1998-12-11
AR070670A2 (es) 2010-04-28
CZ403498A3 (cs) 1999-03-17
CA2257431C (en) 2001-11-20
SI0915701T1 (en) 2005-06-30
TW506836B (en) 2002-10-21
CZ295226B6 (cs) 2005-06-15
ZA975281B (en) 1998-12-14
HRP970321B1 (en) 2001-12-31
BG102991A (en) 1999-08-31
BG64168B1 (bg) 2004-03-31
WO1997047304A1 (en) 1997-12-18
SK169698A3 (en) 1999-10-08
KR20000015851A (ko) 2000-03-15
JP2000511918A (ja) 2000-09-12
DE69732113T2 (de) 2005-12-08
EE03337B1 (et) 2001-02-15
MY121669A (en) 2006-02-28
PT915701E (pt) 2005-05-31
SK284620B6 (sk) 2005-07-01
NO322892B1 (no) 2006-12-18
UA62930C2 (uk) 2004-01-15
ES2235234T3 (es) 2005-07-01
US6099863A (en) 2000-08-08
PL330431A1 (en) 1999-05-10
CN1222077A (zh) 1999-07-07
CA2257431A1 (en) 1997-12-18
ATE285777T1 (de) 2005-01-15
EP0915701B1 (en) 2004-12-29
IL127519A0 (en) 1999-10-28
CN1102390C (zh) 2003-03-05
HRP970321A2 (en) 1998-04-30
KR100358676B1 (ko) 2003-02-17
IL127519A (en) 2002-07-25
DE69732113D1 (de) 2005-02-03
US6358527B1 (en) 2002-03-19
EP0915701A1 (en) 1999-05-19
AU3174397A (en) 1998-01-07
AU726212B2 (en) 2000-11-02
PL189329B1 (pl) 2005-07-29
TR199802592T2 (xx) 1999-03-22
JP4172820B2 (ja) 2008-10-29
NZ333280A (en) 1999-09-29

Similar Documents

Publication Publication Date Title
ID17088A (id) Tablet galantamin hidrobromida yang sangat mudah larut
NO985499D0 (no) Likestr°mstransformator/reaktor
ID26334A (id) Morfolinol yang aktif secara farmasi
ID28110A (id) Surfaktan alkilbenzenasulfonat yang disempurnakan
NO975894L (no) Foringsr°rpakning
DE69716101D1 (de) Wasserundurchlässige gesichtsmaske
DE59707194D1 (de) Direkttablettierhilfsmittel
NO984316D0 (no) Skjµreverkt°y
ID29629A (id) Tablet yang lapas-segera
DE69718481T2 (de) Elektrolyt
DK0966287T3 (da) Oxacarbazepinfilmovertrukne tabletter
NO303590B1 (no) L°pehjul
DE69724336D1 (de) Wasserenthärtende Tabletten
NO990552L (no) Innrettingsverkt°y
ID23735A (id) Tablet trovafloksasin mesilat
ID21770A (id) Plester yang mengandung felbinak
NO305650B1 (no) L°ftejekk
NO985395D0 (no) L°fteanordning
NO992852D0 (no) Basisstr°mningsenhet
DE29705517U1 (de) Sprinkler
ATA198296A (de) Peltonrad - vorspannung
DE29801440U1 (de) Tabletten-Einnahmehilfe
DE29621865U1 (de) Portions-Tablette
NO964898D0 (no) Elektrokjemisk anlegg
ID17786A (id) Sel fotoelektrokima